Haefner Burkhard
Department of Oncology, Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium.
Cancer Treat Res. 2006;130:219-45. doi: 10.1007/0-387-26283-0_10.
After more than three decades of its declaration, the war against cancer still appears far from being won. Although there have been decisive victories in a few battles, such as the one against testicular cancer, the overall result is sobering. Hopes for an imminent cure had been raised among the public by the promises of molecular biology, combinatorial chemistry and high-throughput screening. These promises have manifested themselves in the widely proclaimed strategy of rationally targeted anticancer drug discovery, which may be summarized as the 'one-gene-one target-one drug' approach. Over the years, however, it has gradually become clear that, in most cases, treatment of cancer with a single drug may at best delay progression of the disease but is unlikely to lead to a cure. Thus, it appears that rationally targeted monotherapy will have to be replaced by rationally targeted combination therapy. Inhibitors of NF-kappaB look likely to become an important weapon in the anticancer combination therapy arsenal.
在宣布开展抗癌战争三十多年后，这场战争似乎仍远未取得胜利。尽管在一些战役中取得了决定性胜利，比如针对睾丸癌的战役，但总体结果却令人清醒。分子生物学、组合化学和高通量筛选的承诺曾在公众中唤起了即将攻克癌症的希望。这些承诺体现在广泛宣扬的合理靶向抗癌药物研发策略中，该策略可概括为“一个基因—一个靶点—一种药物”的方法。然而，多年来逐渐变得清晰的是，在大多数情况下，用单一药物治疗癌症充其量只能延缓疾病进展，但不太可能治愈。因此，合理靶向单药治疗似乎将不得不被合理靶向联合治疗所取代。核因子κB抑制剂看起来很可能成为抗癌联合治疗武器库中的一种重要武器。
